ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8281)
◆英語タイトル:ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8281
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. Its pipeline drug candidates include AM0010, AM0015, AM0012, AM0003 and AM0001. ARMO Biosciences’s lead immunotherapy AM0010 is along-acting form of recombinant human Interleukin 10 (IL-10). The company’s AM0001, is a monoclonal antibody that activates T cells by blocking the interaction between the checkpoint inhibitors programmed cell death protein-1 and programmed cell death ligand-1. Its pipeline comprises various validated product candidates aimed at treating a variety of cancers in combination with standard of care and emerging immunotherapies. ARMO Biosciences is headquartered in Redwood City, California, the US.

ARMO Biosciences Inc (ARMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
Venture Financing 12
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
Equity Offering 22
ARMO BioSciences Raises USD128 Million in IPO 22
Acquisition 24
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc – Key Competitors 26
ARMO Biosciences Inc – Key Employees 27
ARMO Biosciences Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Apr 02, 2018: ARMO BioSciences Reports FY 2017 Financial Results 29
Corporate Communications 30
Nov 28, 2017: ARMO BioSciences Appoints Herb Cross as Chief Financial Officer 30
Jun 28, 2017: ARMO BioSciences Appoints Naiyer A. Rizvi, M.D. to Board of Directors 31
Apr 26, 2017: ARMO BioSciences Appoints Pierre Legault to Board of Directors 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
ARMO BioSciences Raises USD128 Million in IPO 22
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc, Key Competitors 26
ARMO Biosciences Inc, Key Employees 27

List of Figures
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報(ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆